83314-01-6
基本信息
化合物 T14831
CS-1164
NSC-339555
BRYOSTATIN
Byrostatin 1
BRYOSTATIN 1
bryostatin1,0
(26R)-Bryostatin 1
Bryostatin 1 - CAS 83314-01-6 - Calbiochem
(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-Methoxy-2-oxoethylidene)-10,10,26,26-tetraMethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-y
物理化学性质
熔点 | 230-235° |
比旋光度 | D25 +34.1° (c = 0.044 in methanol) |
沸点 | 716.44°C (rough estimate) |
密度 | 1.1245 (rough estimate) |
折射率 | 1.5940 (estimate) |
储存条件 | -20°C |
溶解度 | DMSO: soluble |
溶解度 | 可溶于DMSO |
形态 | solid |
颜色 | white |
安全数据
危险性符号(GHS) | GHS07 |
警示词 | 警告 |
危险性描述 | H315-H319-H335-H373 |
防范说明 | P271-P280-P312 |
危险品标志 | Xn |
危险类别码 | 68 |
安全说明 | 22-24/25-36/37 |
WGK Germany | 3 |
WGK Germany | 3 |
RTECS号 | EH9455000 |
海关编码 | 2932990090 |
毒性 | LD50 in mice, rats (mg/kg): 0.038, 0.068 i.v. (Prendiville) |
化合物 T14831价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/08 | HY-105231 | 化合物 T14831 Bryostatin 1 | 83314-01-6 | 10μg | 5200元 |
常见问题列表
PKC
HIV-1
Bryostatin 1 (1 µM; 5 minutes; HT22 cells) treatment successfully recruits Munc13-1 from the cytosol to the plasma membrane. Effects of Bryostatin 1 on the other Munc13 family members, ubMunc13-2 and bMunc13-2, resembled those of Munc13-1 for translocation .
The increased level of expression of Munc13-1 following a 24 h incubation with Bryostatin 1 in both HT22 and primary mouse hippocampal cells is observed.
Bryostatin 1 can also affect the immune system by modulating dendritic cells (DCs) via toll-like receptor 4 (TLR4) through the MyD88-independent pathway, which favors an anti-inflammatory environment by inducing a type 2 phenotype that promotes the differentiation of CD4
+
T-helper (Th) lymphocytes into Th2 versus Th1 effector cells.
Western Blot Analysis
Cell Line: | HT22 cells |
Concentration: | 1 µM |
Incubation Time: | 5 minutes |
Result: | Caused Munc13-1 to transfer to the membrane fraction. |
Bryostatin 1 (30 μg/kg; intraperitoneal injection; 3 d per week; for 2 weeks; C57BL/6J mice) treatment abolishes the onset of EAE.
Animal Model: | Female C57BL/6J mice (8-12-week-old) with MOG 35-55 |
Dosage: | 30 μg/kg |
Administration: | Intraperitoneal injection; 3 d per week; for 2 weeks |
Result: | Abolished the onset of experimental autoimmune encephalomyelitis (EAE). |